Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 77


VivaGel (SPL7013 Gel): a candidate dendrimer--microbicide for the prevention of HIV and HSV infection.

Rupp R, Rosenthal SL, Stanberry LR.

Int J Nanomedicine. 2007;2(4):561-6. Review.


SPL7013 Gel (VivaGel®) retains potent HIV-1 and HSV-2 inhibitory activity following vaginal administration in humans.

Price CF, Tyssen D, Sonza S, Davie A, Evans S, Lewis GR, Xia S, Spelman T, Hodsman P, Moench TR, Humberstone A, Paull JR, Tachedjian G.

PLoS One. 2011;6(9):e24095. doi: 10.1371/journal.pone.0024095. Epub 2011 Sep 15.


Virucidal activity of the dendrimer microbicide SPL7013 against HIV-1.

Telwatte S, Moore K, Johnson A, Tyssen D, Sterjovski J, Aldunate M, Gorry PR, Ramsland PA, Lewis GR, Paull JR, Sonza S, Tachedjian G.

Antiviral Res. 2011 Jun;90(3):195-9. doi: 10.1016/j.antiviral.2011.03.186. Epub 2011 Apr 1.


Evaluation of dendrimer SPL7013, a lead microbicide candidate against herpes simplex viruses.

Gong E, Matthews B, McCarthy T, Chu J, Holan G, Raff J, Sacks S.

Antiviral Res. 2005 Dec;68(3):139-46. Epub 2005 Sep 27.


Structure activity relationship of dendrimer microbicides with dual action antiviral activity.

Tyssen D, Henderson SA, Johnson A, Sterjovski J, Moore K, La J, Zanin M, Sonza S, Karellas P, Giannis MP, Krippner G, Wesselingh S, McCarthy T, Gorry PR, Ramsland PA, Cone R, Paull JR, Lewis GR, Tachedjian G.

PLoS One. 2010 Aug 23;5(8):e12309. doi: 10.1371/journal.pone.0012309.


Preclinical safety and efficacy assessments of dendrimer-based (SPL7013) microbicide gel formulations in a nonhuman primate model.

Patton DL, Cosgrove Sweeney YT, McCarthy TD, Hillier SL.

Antimicrob Agents Chemother. 2006 May;50(5):1696-700.


Phase 1 randomized trial of the vaginal safety and acceptability of SPL7013 gel (VivaGel) in sexually active young women (MTN-004).

McGowan I, Gomez K, Bruder K, Febo I, Chen BA, Richardson BA, Husnik M, Livant E, Price C, Jacobson C; MTN-004 Protocol Team.

AIDS. 2011 May 15;25(8):1057-64. doi: 10.1097/QAD.0b013e328346bd3e.


Dendrimers as drugs: discovery and preclinical and clinical development of dendrimer-based microbicides for HIV and STI prevention.

McCarthy TD, Karellas P, Henderson SA, Giannis M, O'Keefe DF, Heery G, Paull JR, Matthews BR, Holan G.

Mol Pharm. 2005 Jul-Aug;2(4):312-8. Review.


SPL7013 gel as a topical microbicide for prevention of vaginal transmission of SHIV89.6P in macaques.

Jiang YH, Emau P, Cairns JS, Flanary L, Morton WR, McCarthy TD, Tsai CC.

AIDS Res Hum Retroviruses. 2005 Mar;21(3):207-13.


Safety, tolerability, and pharmacokinetics of SPL7013 gel (VivaGel): a dose ranging, phase I study.

O'Loughlin J, Millwood IY, McDonald HM, Price CF, Kaldor JM, Paull JR.

Sex Transm Dis. 2010 Feb;37(2):100-4. doi: 10.1097/OLQ.0b013e3181bc0aac.


Sulfated K5 Escherichia coli polysaccharide derivatives: A novel class of candidate antiviral microbicides.

Rusnati M, Vicenzi E, Donalisio M, Oreste P, Landolfo S, Lembo D.

Pharmacol Ther. 2009 Sep;123(3):310-22. doi: 10.1016/j.pharmthera.2009.05.001. Epub 2009 May 14. Review.


Mechanistic Studies of Viral Entry: An Overview of Dendrimer-Based Microbicides As Entry Inhibitors Against Both HIV and HSV-2 Overlapped Infections.

Sepúlveda-Crespo D, Ceña-Díez R, Jiménez JL, Ángeles Muñoz-Fernández M.

Med Res Rev. 2017 Jan;37(1):149-179. doi: 10.1002/med.21405. Epub 2016 Aug 12. Review.


A randomized controlled trial of the safety of candidate microbicide SPL7013 gel when applied to the penis.

Chen MY, Millwood IY, Wand H, Poynten M, Law M, Kaldor JM, Wesselingh S, Price CF, Clark LJ, Paull JR, Fairley CK.

J Acquir Immune Defic Syndr. 2009 Apr 1;50(4):375-80. doi: 10.1097/QAI.0b013e318198a7e6.


Formulating a sulfonated antiviral dendrimer in a vaginal microbicidal gel having dual mechanisms of action.

Mumper RJ, Bell MA, Worthen DR, Cone RA, Lewis GR, Paull JR, Moench TR.

Drug Dev Ind Pharm. 2009 May;35(5):515-24. doi: 10.1080/03639040802488097.


Dendrimers, a new class of candidate topical microbicides with activity against herpes simplex virus infection.

Bourne N, Stanberry LR, Kern ER, Holan G, Matthews B, Bernstein DI.

Antimicrob Agents Chemother. 2000 Sep;44(9):2471-4.


A modified zinc acetate gel, a potential nonantiretroviral microbicide, is safe and effective against simian-human immunodeficiency virus and herpes simplex virus 2 infection in vivo.

Kenney J, Rodríguez A, Kizima L, Seidor S, Menon R, Jean-Pierre N, Pugach P, Levendosky K, Derby N, Gettie A, Blanchard J, Piatak M Jr, Lifson JD, Paglini G, Zydowsky TM, Robbiani M, Fernández Romero JA.

Antimicrob Agents Chemother. 2013 Aug;57(8):4001-9. doi: 10.1128/AAC.00796-13. Epub 2013 Jun 10.


Development of topical microbicides for prevention of human immunodeficiency virus and herpes simplex virus.

Keller MJ, Klotman ME, Herold BC.

Am J Reprod Immunol. 2003 May;49(5):279-84. Review.


PRO 2000 gel inhibits HIV and herpes simplex virus infection following vaginal application: a double-blind placebo-controlled trial.

Keller MJ, Zerhouni-Layachi B, Cheshenko N, John M, Hogarty K, Kasowitz A, Goldberg CL, Wallenstein S, Profy AT, Klotman ME, Herold BC.

J Infect Dis. 2006 Jan 1;193(1):27-35. Epub 2005 Nov 17.


"Tell Juliana": acceptability of the candidate microbicide VivaGel® and two placebo gels among ethnically diverse, sexually active young women participating in a phase 1 microbicide study.

Carballo-Diéguez A, Giguere R, Dolezal C, Chen BA, Kahn J, Zimet G, Mabragaña M, Leu CS, McGowan I.

AIDS Behav. 2012 Oct;16(7):1761-74.


Prioritizing prevention of HIV and sexually transmitted infections: first-generation vaginal microbicides.

Madan RP, Keller MJ, Herold BC.

Curr Opin Infect Dis. 2006 Feb;19(1):49-54. Review.


Supplemental Content

Support Center